Federica Pecci

1.4k total citations
61 papers, 442 citations indexed

About

Federica Pecci is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Cancer Research. According to data from OpenAlex, Federica Pecci has authored 61 papers receiving a total of 442 indexed citations (citations by other indexed papers that have themselves been cited), including 49 papers in Oncology, 37 papers in Pulmonary and Respiratory Medicine and 12 papers in Cancer Research. Recurrent topics in Federica Pecci's work include Lung Cancer Treatments and Mutations (22 papers), Cancer Immunotherapy and Biomarkers (16 papers) and Lung Cancer Research Studies (13 papers). Federica Pecci is often cited by papers focused on Lung Cancer Treatments and Mutations (22 papers), Cancer Immunotherapy and Biomarkers (16 papers) and Lung Cancer Research Studies (13 papers). Federica Pecci collaborates with scholars based in Italy, United States and Netherlands. Federica Pecci's co-authors include Rossana Berardi, Luca Cantini, Silvia Rinaldi, Joachim G.J.V. Aerts, Andrea Lanese, Biagio Ricciuti, Giuseppe Lamberti, Ilaria Fiordoliva, Robert A. Belderbos and Robin Cornelissen and has published in prestigious journals such as Nature Communications, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

In The Last Decade

Federica Pecci

51 papers receiving 434 citations

Peers

Federica Pecci

ONCOL

PRM

SURGE

Yingjian Song China

Yoshitaka Seki Japan

Georgios Tsakonas Sweden

Sonam Puri United States

Amparo Sánchez-Gastaldo Spain

Anna Kryzhanivska Ukraine

Kouki Ohtsuka Japan

Maria Grazia Rodriquenz Italy

Marta Soares Portugal

Yuming Rong China

Yingjian Song China

Federica Pecci

192 ×0.7

ONCOL

133 ×0.7

PRM

102 ×1.0

99 ×1.0

46 ×0.8

SURGE

Citations per year, relative to Federica Pecci Federica Pecci (= 1×) peers Yingjian Song

Countries citing papers authored by Federica Pecci

Since Specialization

Citations

This map shows the geographic impact of Federica Pecci's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Federica Pecci with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Federica Pecci more than expected).

Fields of papers citing papers by Federica Pecci

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Federica Pecci. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Federica Pecci. The network helps show where Federica Pecci may publish in the future.

Co-authorship network of co-authors of Federica Pecci

This figure shows the co-authorship network connecting the top 25 collaborators of Federica Pecci. A scholar is included among the top collaborators of Federica Pecci based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Federica Pecci. Federica Pecci is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Pecci, Federica, et al.. (2025). 358P: Baseline circulating immunophenotype may predict irAEs onset in NSCLC patients treated with ICIs. Journal of Thoracic Oncology. 20(3). S213–S213. 1 indexed citations

Rebuzzi, Sara Elena, Giulia Mazzaschi, Federica Pecci, et al.. (2025). The prognostic value of the haemoglobin/red cell distribution width ratio in a cohort of pre-treated patients with renal cell carcinoma receiving nivolumab. Cancer Treatment and Research Communications. 43. 100927–100927.

Odintsov, Igor, Mark M. Hammer, Biagio Ricciuti, et al.. (2025). The Genomic Landscape of NSCLC in Systemic Sclerosis Reveals Frequent TP53 Mutations and a Paucity of Actionable Oncogenes. Journal of Thoracic Oncology. 21(3). 103501–103501.

Odintsov, Igor, Federica Pecci, Mihaela Aldea, et al.. (2025). Efficacy and Safety of Tarlatamab in a Patient With Advanced Delta-Like Ligand 3-Positive Large Cell Neuroendocrine Lung Carcinoma and Untreated Brain Metastases: A Case Report. JCO Precision Oncology. 9(9). e2500184–e2500184. 1 indexed citations

Manini, M.A., Federica Pecci, Giulia Mazzaschi, et al.. (2025). 362P: LIPI score in advanced NSCLC treated with ICIs: Prognostic impact and blood immune-inflammatory correlations. Journal of Thoracic Oncology. 20(3). S215–S215.

D’Agnelli, Simona, et al.. (2025). Molecular heterogeneity of small cell lung cancer and new therapeutic possibilities: a narrative review of the literature. Translational Lung Cancer Research. 14(4). 1441–1455. 1 indexed citations

Ricciuti, Biagio, Rohit Thummalapalli, Fabrizio Citarella, et al.. (2024). Clinical outcomes and post-progression retreatment in patients with metastatic NSCLC who complete two years of treatment with immune checkpoint blockade.. Journal of Clinical Oncology. 42(16_suppl). 8633–8633.

Vaz, Victor R., Biagio Ricciuti, Joao V. Alessi, et al.. (2024). Response to Crizotinib After Entrectinib Resistance in ROS1 -Rearranged, MET -Amplified Lung Adenocarcinoma. JCO Precision Oncology. 8(8). e2400394–e2400394.

Mazzaschi, Giulia, Fabiana Perrone, Giuseppe Maglietta, et al.. (2024). Intersecting Blood Cytokines With Cholesterol Parameters to Profile Patients With Advanced Solid Tumors Receiving Immune Checkpoint Inhibitors. Journal of Immunotherapy. 47(9). 388–394. 2 indexed citations

10.

Alessi, Joao V., Adam Price, Allison L. Richards, et al.. (2023). Multi-institutional analysis of aneuploidy and outcomes to chemoradiation and durvalumab in stage III non-small cell lung cancer. Journal for ImmunoTherapy of Cancer. 11(11). e007618–e007618. 5 indexed citations

11.

Lamberti, Giuseppe, Ayal A. Aizer, Biagio Ricciuti, et al.. (2023). Incidence of Brain Metastases and Preliminary Evidence of Intracranial Activity With Sotorasib in Patients With KRAS^G12C-Mutant Non–Small-Cell Lung Cancer. JCO Precision Oncology. 7(7). e2200621–e2200621. 12 indexed citations

12.

Ricciuti, Biagio, Melissa Gildenberg, Ankit Singh, et al.. (2023). Amplification of wild-type RET and clinical response to selpercatinib for non–small-cell lung cancer (NSCLC).. Journal of Clinical Oncology. 41(16_suppl). 9123–9123. 1 indexed citations

13.

Parisi, Alessandro, et al.. (2023). Current Evidence and Future Perspectives about the Role of PARP Inhibitors in the Treatment of Thoracic Cancers. OncoTargets and Therapy. Volume 16. 585–613. 2 indexed citations

14.

Federico, Alessandro Di, Biagio Ricciuti, Joao V. Alessi, et al.. (2023). MA20.06 Association of TTF-1 Expression with Outcomes to Immunotherapy and KRAS G12C Inhibition in Lung Adenocarcinoma. Journal of Thoracic Oncology. 18(11). S175–S175.

15.

Pretta, Andrea, Pina Ziranu, Riccardo Giampieri, et al.. (2022). Influence of antidiabetic drugs on glucose metabolism and immune response in patients with metastatic pancreatic ductal adenocarcinoma receiving gemcitabine plus nab-paclitaxel as first-line treatment. Digestive and Liver Disease. 55(5). 655–660. 2 indexed citations

16.

Bittoni, Alessandro, Riccardo Giampieri, Federica Pecci, et al.. (2021). Retrospective Cohort Study of Caveolin-1 Expression as Prognostic Factor in Unresectable Locally Advanced or Metastatic Pancreatic Cancer Patients. Current Oncology. 28(5). 3525–3536. 1 indexed citations

17.

Cantini, Luca, Giulia Mentrasti, Nicla La Verde, et al.. (2021). 35P Lung cancer diagnosis and continuum of care: How did the COVID-19 outbreak impact? Data from an Italian multicenter study. Journal of Thoracic Oncology. 16(4). S713–S713. 1 indexed citations

18.

Bittoni, Alessandro, Federica Pecci, Giulia Mentrasti, et al.. (2021). Systemic immune-inflammation index: a prognostic tiebreaker among all in advanced pancreatic cancer. Annals of Translational Medicine. 9(3). 251–251. 31 indexed citations

19.

Berardi, Rossana, Giulia Mentrasti, Nicla La Verde, et al.. (2021). 1609P COVID-19 outbreak repercussions on breast cancer diagnoses and access to treatment: Preliminary data from the COVID-DELAY study. Annals of Oncology. 32. S1149–S1149. 1 indexed citations

20.

Giampieri, Riccardo, Antonio Zizzi, Alessandro Bittoni, et al.. (2020). P-27 Retrospective observational analysis of p53 mutational status as a prognostic factor in TAS-102 treated metastatic colorectal cancer patients. Annals of Oncology. 31. S98–S98. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact